Announced details
Intracellular transport of active metabolites of antibody-drug conjugates, and research on the mechanisms of drug efficacy and resistance in breast cancer therapies
Co-researcher for the co-authored paper with Tokyo University of Pharmacy and Life Sciences. The paper lists the Laboratory of Pharmacokinetic Control, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, and 株式会社ペルセウスプロテオミクス as authors.
Laboratory of Pharmacokinetic Control, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences. Other locations, representative, capital, and year established: Not disclosed
DOI: 10.1021/acs.molpharmaceut.6c00535
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Molecular Pharmaceutics
| Item | Details |
|---|---|
| Names of Products / Services Covered | Anti-MMAE antibody |
| Counterparty | Tokyo University of Pharmacy and Life Sciences |
| Counterparty overview | Laboratory of Pharmacokinetic Control, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences. Other locations, representative, capital, and year established: Not disclosed |
| Relationship with the Company | Co-researcher for the co-authored paper with Tokyo University of Pharmacy and Life Sciences. The paper lists the Laboratory of Pharmacokinetic Control, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, and 株式会社ペルセウスプロテオミクス as authors. |
| Applicable area | Intracellular transport of active metabolites of antibody-drug conjugates, and research on the mechanisms of drug efficacy and resistance in breast cancer therapies |
| Registration number and expiry date | DOI: 10.1021/acs.molpharmaceut.6c00535 |
| Source | Molecular Pharmaceutics |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To disclose research findings elucidating SLC46A3’s drug transport function using the anti-MMAE antibody developed and commercialized by our company.